[Apparelyzed]

Maryland’s Neuralstem raises $5 million
March 19, 2007

ROCKVILLE, MD—Neuralstem Inc., which is developing stem cell therapies, has raised $5.1 million in a private placement.

Neuralstem plans to use proceeds from the placement for its anticipated first human trial, as well as working capital and other general corporate purposes.

Neuralstem president and CEO Richard Garr says, "We view the placement as solidifying the company's balance sheet in preparation for national exchange listing, as well as providing equity capital sufficient to fund our first human trials expected to begin during calendar 2007."

Neuralstem Inc. is a biotechnology company developing treatments based on the transplantation of human neural stem cells.

Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

The company hopes to submit its initial investigational new drug (IND) application to the FDA and begin its first human trial during 2007.

Major central nervous system diseases targeted by the company with research programs currently underway include: ischemic spastic paraplegia, traumatic spinal cord injury, ALS, and Parkinson's Disease. The company has also developed immortalized human neural stem cells for in-vitro use in drug development for the academic and pharmaceutical markets.

The company's cells recently extended the life of rats with ALS (Lou Gehrig's disease).

For more information see: http://www.neuralstem.com.